FindTrial
Sign In

Susceptibility of Ceftriaxone on infections

In vitro susceptibility of Ceftriaxone or Ceftriaxone combination with Sulbactam & Tazobactam in community acquired and nosocomial infections against gram-negative and gram -positive bacteria

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/04/041997
Enrollment
180
Registered
2022-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B950- Streptococcus, group A, as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Alkem Laboratories
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 180 Non-repetitive clinical samples such as blood, urine, respiratory samples, tissue, pus, cerebrospinal fluid (CSF), ascetic fluid etc.

Exclusion criteria

Exclusion criteria: Clinical isolates from repeat cultures performed during in-patient follow-up that were previously recruited into the study

Design outcomes

Primary

MeasureTime frame
1. To evaluate in vitro susceptibility of Ceftriaxone alone and Ceftriaxone in combination with Tazobactam and Sulbactam against gram positive and gram negative bacteria 2. Antibiotic sensitivity of Ceftriaxone alone and Ceftriaxone in combination with Tazobactam and Sulbatam in extended-spectrum beta-lactamase (ESBL)- and metallo-beta-lactamse (MBL)-producing isolates.Timepoint: 1. Minimum inhibitory concentration of Ceftriaxone alone and Ceftriaxone in combination with Tazobactam and Sulbactam against gram positive and gram negative bacteria using E-Test Method 2. Minimum inhibitory concentration of Ceftriaxone alone and Ceftriaxone in combination with Tazobactam and Sulbactam in gram negative bacteria extended-spectrum beta-lactamase (ESBL)- and metallo-beta-lactamse (MBL)-producing isolates.—

Secondary

MeasureTime frame
1. To evaluate in vitro susceptibility of Ceftriaxone alone and Ceftriaxone in combination with Tazobactam and Sulbactam compared to other broad spectrum antibiotics such as Amoxycillin clavulanate, Cefotaxime, Piperacillin Tazobactam, Cefipime against gram positive and gram negative bacteria.Timepoint: To evaluate minimum inhibitory concentration of Ceftriaxone alone and Ceftriaxone in combination with Tazobactam and Sulbactam against gram positive and gram negative bacteria using E-Test Method broad spectrum antibiotics such as Amoxycillin clavulanate, Cefotaxime, Piperacillin Tazobactam, Cefipime against gram positive and gram negative bacteria—

Countries

India

Contacts

Public ContactDr Anindita Chatterjee

Alkem Laboratories

anindita.chatterjee@alkem.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026